Company Overview and News

22
Your Daily Scoop: Five Prime Progresses, Endocyte's rPFS And Stock Offering, Tracon's Results Published

2018-09-12 seekingalpha - 5
Discussion: Five Prime Therapeutics' (FPRX) FPA144 (bemarituzumab) plus chemotherapy completed Part 1 of a Phase 1/3 clinical trial evaluating treatment-naive patients with advanced gastric cancer (GC) or cancer of the gastroesophageal junction (GEJ). The trial now moves to its subsequent parts in Phase 3. Overall survival (OS) is the primary endpoint of the trial. Progression-free survival (PFS) and objective response rate (ORR) are the secondary endpoints.
CYCC MASI CYCCP ECYT JNJ ZLAB PRGO FPRX TCON

11
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-09-07 sec.gov - 8
tcon-8k_20180906.htm
TCON

4
TCON / TRACON Pharmaceuticals, Inc. 424B5 (Prospectus)

2018-09-07 sec.gov - 1
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209313 PROSPECTUS SUPPLEMENT (to the Prospectus Dated April 4, 2016)
TCON

4
TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference

2018-08-29 globenewswire - 1
SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate update at the 2018 Wells Fargo Healthcare Conference at 9:05 pm EDT on Wednesday, September 5, 2018, at the Westin Waterfront in Boston, MA.
TCON

4
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 1
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Second Quarter 2018 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.
NCIT TCON

3
TCON / TRACON Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
tcon-10q_20180630.htm UNITED STATES
TCON

3
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
tcon-8k_20180808.htm
TCON

8
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-10 sec.gov - 5
tcon-8k_20180710.htm
TCON

14
TCON / TRACON Pharmaceuticals, Inc. null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S(P M,#@O3R [email protected],C
TCON

14
TCON / TRACON Pharmaceuticals, Inc. null

2018-06-24 sec.gov
tcon-corresp.htm TRACON Pharmaceuticals, Inc.
TCON

22
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-15 sec.gov - 8
tcon-8k_20180613.htm
TCON

164
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

2018-06-15 seekingalpha - 4
Wright Medical Group N.V. (WMGI) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF-BB) and a blend of Type I collagen and Beta tricalcium phosphate. The combination is used as a safe and effective alternative to autograft for use in hindfoot and ankle fusion in an easy to use flowable formulation.
SGEN REGN CUTR K RVVTF SCPH PULM AGN MRK CRBP CAH CLSD TCON RVV

16
TCON / TRACON Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-13 sec.gov - 2
tcon-8k_20180613.htm
TCON

15
TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

2018-05-31 globenewswire - 1
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY.
TCON

14
TRACON Pharmaceuticals Reports Granting of Inducement Award

2018-05-31 globenewswire
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has issued an inducement award to a new executive employee.
TCON

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TCON / TRACON Pharmaceuticals, Inc. on message board site Silicon Investor.

SatCon Technology (SATC) SatCon Technology (SATC) SatCon Technology (SATC) Netconversions.com Netconversions.com Netconversions.com
The New Dotconomy The New Dotconomy The New Dotconomy Rhythms NetConnections Inc. (RTHM) Rhythms NetConnections Inc. (RTHM) Rhythms NetConnections Inc. (RTHM)
CUSIP: 89237H100